[SCHEDULE 13G] Yarrow Bioscience, Inc. Passive Investment Disclosure (>5%)
Yarrow Bioscience: Bellevue reports 10.6% stake
Bellevue Group AG, on behalf of its wholly owned subsidiary Bellevue Asset Management AG, reported beneficial ownership of 1,000,000 shares of Yarrow Bioscience, Inc. (YARW), with shared voting and dispositive power over that position.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Bellevue Group AG, on behalf of its wholly owned subsidiary Bellevue Asset Management AG, reported beneficial ownership of 1,000,000 shares of Yarrow Bioscience, Inc. (YARW), with shared voting and dispositive power over that position. The reported 10.6% of the class is based on 9,437,693 Yarrow shares outstanding as of September 14, 2026, after giving effect to the closing of Yarrow’s equity offering on that date.
Key Figures
Shares beneficially owned:1,000,000 sharesPercent of class:10.6%Shares outstanding:9,437,693 shares
3 metrics
Shares beneficially owned1,000,000 sharesBellevue Group AG and Bellevue Asset Management AG
Percent of class10.6%Based on shares outstanding as of September 14, 2026
Shares outstanding9,437,693 sharesAs of September 14, 2026, after giving effect to the closing of an equity offering
Key Terms
beneficial ownership, shared voting power, shared dispositive power
3 terms
beneficial ownershipregulatory
"percentages of beneficial ownership contained herein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerregulatory
"Shared voting power: 1,000,000"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared dispositive power: 1,000,000"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many YARW shares does Bellevue report beneficially owning?
Bellevue Group AG, on behalf of its wholly owned subsidiary Bellevue Asset Management AG, reported beneficial ownership of 1,000,000 Yarrow Bioscience shares, equal to 10.6% of the class. The two entities reported shared voting and dispositive power over 1,000,000 shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Yarrow Bioscience, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
92941V407
(CUSIP Number)
09/10/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92941V407
1
Names of Reporting Persons
Bellevue Group AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,000,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,000,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,000,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.6 %
12
Type of Reporting Person (See Instructions)
HC, CO
Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 9,437,693 shares of Common Stock outstanding as of September 14, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on September 11, 2026.
SCHEDULE 13G
CUSIP Number(s):
92941V407
1
Names of Reporting Persons
Bellevue Asset Management AG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,000,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,000,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,000,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.6 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 9,437,693 shares of Common Stock outstanding as of September 14, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on September 11, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Yarrow Bioscience, Inc.
(b)
Address of issuer's principal executive offices:
470 James Street, Suite 007, New Haven, CT 06513
Item 2.
(a)
Name of person filing:
Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)
Address or principal business office or, if none, residence:
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
1,000,000
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
